- Home
- INV vs CRVS Comparison
INV vs CRVS Comparison
Compare INV & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- CRVS
- Stock Information
- Founded
- INV 2015
- CRVS 2014
- Country
- INV United States
- CRVS United States
- Employees
- INV N/A
- CRVS N/A
- Industry
- INV
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- CRVS Health Care
- Exchange
- INV NYSE
- CRVS Nasdaq
- Market Cap
- INV 448.7M
- CRVS 451.0M
- IPO Year
- INV N/A
- CRVS 2016
- Fundamental
- Price
- INV $10.66
- CRVS $8.94
- Analyst Decision
- INV
- CRVS Buy
- Analyst Count
- INV 0
- CRVS 4
- Target Price
- INV N/A
- CRVS $12.83
- AVG Volume (30 Days)
- INV 19.2K
- CRVS 1.0M
- Earning Date
- INV 11-14-2024
- CRVS 11-12-2024
- Dividend Yield
- INV N/A
- CRVS N/A
- EPS Growth
- INV N/A
- CRVS N/A
- EPS
- INV N/A
- CRVS N/A
- Revenue
- INV $988,000.00
- CRVS N/A
- Revenue This Year
- INV N/A
- CRVS N/A
- Revenue Next Year
- INV N/A
- CRVS N/A
- P/E Ratio
- INV N/A
- CRVS N/A
- Revenue Growth
- INV 4.88
- CRVS N/A
- 52 Week Low
- INV $8.55
- CRVS $1.30
- 52 Week High
- INV $18.75
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- INV N/A
- CRVS 60.34
- Support Level
- INV N/A
- CRVS $8.02
- Resistance Level
- INV N/A
- CRVS $8.71
- Average True Range (ATR)
- INV 0.00
- CRVS 0.86
- MACD
- INV 0.00
- CRVS -0.17
- Stochastic Oscillator
- INV 0.00
- CRVS 52.25
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).